Skip to main content
OpenTrials
Completed

NCT Number: NCT04605458

Contingency Management to Promote Smoking Abstinence in Cancer Patients

This is a smoking cessation treatment study. Patients who have a cancer or a suspected cancer who will undergo surgical removal of their cancer are eligible to participate in this study. A novel smoking cessation treatment will be provided to half of the participants in the study. All study participants will receive standard smoking cessation therapy including counseling and the nicotine patch.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Smoking Cessation Behavior Health Behavior

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Medical University of South Carolina

Charleston, South Carolina, 29425, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 or older
  • smoking 1 or more combustible tobacco products per day
  • diagnosed with or suspicion of any type of operable cancer

Exclusion criteria

  • unstable psychiatric/medical conditions such as suicidal ideation, acute psychosis, or dementia
  • non-English speaking
  • use of alternative nicotine delivery systems (e.g., e-cigarettes, snus, etc)
  • pregnant women

Treatment and study plan

Contingency Management

Combination Product

Participants will receive 3-6 counseling sessions, nicotine patches & lozenges, and monetary payment delivered contingent on abstinence verified by CO breath test.

Standard Care

Combination Product

Participants will receive 3-6 counseling sessions, nicotine patches & lozenges, and CO breath test monitoring.

Primary outcomes

  1. Abstinence Rates as Assessed by Self-report for Past 7 Days, Carbon Monoxide Breath Monitoring and/or Anabasine Testing

    Time frame: Changes between the study intake appointment to day of surgery, up to five weeks apart

    Abstinence will be defined by 7 days by self-report of no tobacco products, confirmed by CO breath test less than or equal to 4ppm and/or urine anabasine levels less than or equal to 2 ng/ml

Secondary outcomes

  1. Abstinence Rates as Assessed by Self-report for Past 7 Days, Carbon Monoxide Breath Monitoring and/or Anabasine Testing

    Time frame: Three months after surgery date

    Abstinence will be defined by 7 days by self-report of no tobacco products, confirmed by CO breath test less than or equal to 4ppm and/or urine anabasine levels less than or equal to 2 ng/ml

  2. Abstinence Rates as Assessed by Self-report for Past 7 Days, Carbon Monoxide Breath Monitoring and/or Anabasine Testing

    Time frame: Six months after surgery date

    Abstinence will be defined by 7 days by self-report of no tobacco products, confirmed by CO breath test less than or equal to 4ppm and/or urine anabasine levels less than or equal to 2 ng/ml

Sponsors and collaborators

Lead sponsor

Medical University of South Carolina

Other

Collaborators

  • National Cancer Institute (NCI)

Registry information

Important dates

Study start
2020
Primary completion
2025
Study completion
2025
First posted
Oct 28, 2020
Registry last updated
Aug 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.